PT  - JOURNAL ARTICLE
AU  - Castro, Mateus V. de
AU  - Santos, Keity S.
AU  - Apostolico, Juliana S.
AU  - Fernandes, Edgar R.
AU  - Almeida, Rafael R.
AU  - Levin, Gabriel
AU  - Magawa, Jhosiene Y.
AU  - S. Nunes, João Paulo
AU  - Bruni, Miriam
AU  - Yamamoto, Marcio M.
AU  - Lima, Ariane C.
AU  - Silva, Monize V. R.
AU  - Matos, Larissa R. B.
AU  - Coria, Vivian R.
AU  - Castelli, Erick C.
AU  - Scliar, Marilia O.
AU  - Kuramoto, Andreia
AU  - Bruno, Fernanda R.
AU  - Jacintho, Lucas C.
AU  - Nunes, Kelly
AU  - Wang, Jaqueline Y. T.
AU  - Coelho, Veronica P.
AU  - Neto, Miguel Mitne
AU  - Maciel, Rui M. B.
AU  - Naslavsky, Michel S.
AU  - Passos-Bueno, Maria Rita
AU  - Boscardin, Silvia B.
AU  - Rosa, Daniela S.
AU  - Kalil, Jorge
AU  - Zatz, Mayana
AU  - Cunha-Neto, Edecio
TI  - “Monozygotic twins discordant for severe clinical recurrence of COVID-19 show drastically distinct T cell responses to SARS-Cov-2”
AID  - 10.1101/2021.03.26.21253645
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.26.21253645
4099  - http://medrxiv.org/content/early/2021/03/28/2021.03.26.21253645.short
4100  - http://medrxiv.org/content/early/2021/03/28/2021.03.26.21253645.full
AB  - Background Clinical recurrence of COVID-19 in convalescent patients has been reported, which immune mechanisms have not been thoroughly investigated. Presence of neutralizing antibodies suggests other types of immune response are involved.Methods We assessed the innate type I/III IFN response, T cell responses to SARS-CoV-2 with IFNγ ELISPOT, binding and neutralizing antibody assays, in two monozygotic twin pairs with one COVID-19 recurrence case.Results In pair 1, four months after a first mild episode of infection for both siblings, one displayed severe clinical recurrence of COVID-19. Twin pair 2 of siblings underwent non-recurring asymptomatic infection. All fours individuals presented similar overall responses, except for remarkably difference found in specific cellular responses. Recurring sibling presented a reduced number of recognized T cell epitopes as compared to the other three including her non-recurring sibling.Conclusions Our results suggest that an effective SARS-CoV-2-specific T cell immune response is key for complete viral control and avoidance of clinical recurrence of COVID-19. Besides, adaptive immunity can be distinct in MZ twins. Given the rising concern about SARS-CoV-2 variants that evade neutralizing antibodies elicited by vaccination or infection, our study stresses the importance of T cell responses in protection against recurrence/reinfection.Key points Immune parameters leading to COVID-19 recurrence/reinfection are incompletely understood. A COVID-19 recurrence case in a monozygotic twin pair is described with an intact antibody and innate type I/III Interferon response and drastically reduced number of recognized SARS-CoV-2 T cell epitopes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective study on the SARS-CoV-2 infection (COVID-19) in monozygotic twins Funding StatementThis work was supported by the Sao Paulo Research Foundation (FAPESP) [grant numbers 2013/08028-1, 2014/50890-5, 2014/50931-3 and 2020/09702-1], the National Council for Scientific and Technological Development (CNPq) [grant numbers 465434/2014-2 and 465355/2014-5] and JBS S.A [grant number 69004].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Committee for Ethics in Research of the Institute of Biosciences at the University of Sao Paulo (CAAE 34786620.2.0000.5464) and all participants (or their parents) provided a written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level raw sequencing and immunological data can be shared upon reasonable request, as well as corresponding phenotypes.